Mansour Diana
Graingerville Clinic, Newcastle General Hospital, Newcastle upon Tyne, UK.
Best Pract Res Clin Obstet Gynaecol. 2007 Dec;21(6):1007-21. doi: 10.1016/j.bpobgyn.2007.03.023. Epub 2007 Jun 1.
Since its launch, more than 9 million women worldwide have used the levonorgestrel intra-uterine system (IUS) for contraception, as a treatment for heavy menstrual bleeding and as the progestogen component of hormone-replacement therapy. For women in their reproductive years, the IUS has become one of the most acceptable medical treatments for menorrhagia, reducing referrals to specialists and decreasing the need for operative gynaecological surgery. This article will outline the development of the IUS, highlighting the most important recent areas of research covering its use to control menstrual blood loss and pain.
自左炔诺孕酮宫内节育系统（IUS）推出以来，全球已有超过900万女性将其用于避孕、治疗月经过多以及作为激素替代疗法的孕激素成分。对于处于生育年龄的女性来说，IUS已成为治疗月经过多最可接受的医学疗法之一，减少了转诊至专科医生的情况，并降低了妇科手术的必要性。本文将概述IUS的发展历程，重点介绍其在控制月经失血和疼痛方面应用的近期最重要研究领域。
